This study is developing new blood tests to help diagnose liver conditions like NAFLD (Non-Alcoholic Fatty Liver Disease) and NASH (Non-Alcoholic Steatohepatitis) with fibrosis. Researchers are looking for specific markers in your blood that can show if you have these conditions and how severe they are. The study will analyze blood samples using the AGED Multiple Target Assay to find these markers in healthy people, those with NAFLD, and those with liver fibrosis. The goal is to create a reliable blood test that can tell the difference between these conditions and stage the fibrosis. You can join if you are between 18 and 65 years old and have had a liver biopsy in the past 1-2 years, or if you are considered healthy, or have conditions like metabolic syndrome, NAFLD, fibrosis/cirrhosis, cardiovascular disease, or chronic kidney disease. The study aims to enroll 400 participants, but its current status is unclear.

Study design

This interventional study plans to enroll 400 participants to test new diagnostic methods for liver disease.

What's involved

The study involves collecting blood samples for analysis and comparing them with liver tissue samples. The primary endpoint assessment is measured at 6-9 months.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoints are measured at 6-9 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.